For generations, cancer has often announced itself too late — a diagnosis arriving only after the body has already begun to struggle. Now, a blood test developed by US company Grail offers a quieter form of vigilance, scanning the bloodstream for genetic fragments shed by tumors across more than fifty cancer types before a single symptom appears. Tested on thousands of patients and showing a false-positive rate of just 0.5 percent, the technology stands at the threshold of large-scale NHS trials, carrying with it the hope that early detection — long medicine's most elusive ambition — may at la
Blood test shows promise detecting 50+ cancer types in over-50s
Catching cancer's whisper before it becomes a shout
Mark
Why does it matter that the test catches some cancers at 65 percent but others at lower rates? Isn't any detection better than none?
Mimi
The difference tells you something crucial about which cancers are hardest to catch and which ones are already being caught by other means. Pancreatic cancer kills fast and has no good screening test—so 65 percent detection there is genuinely transformative. But breast cancer already has mammography. This test isn't meant to replace that; it's meant to catch what we're missing.
Mark
The false positive rate is 0.5 percent. That sounds tiny. What does that actually mean for someone getting the test?
Mimi
Out of two hundred people without cancer, one person gets told they might have it when they don't. That person then needs follow-up tests. It's not nothing—it causes anxiety and uses resources—but it's low enough that the benefit of catching real cancers early outweighs the harm.
Mark
Why is the NHS waiting until 2023 for results? That seems like a long time.
Mimi
They're testing 140,000 people. You need time for cancers to either develop or not develop, for people to get diagnosed through other means, for the data to be collected and analyzed properly. You can't rush this. If you get it wrong at scale, you've wasted resources and eroded trust.
Mark
The test identifies tissue location in 88.7 percent of cases. Why is that important?
Mimi
Because if the test says cancer is present, doctors need to know where to look. A positive result without location information sends you on a wild hunt. Knowing it's likely in the pancreas or lungs narrows the search dramatically and gets people to treatment faster.
Mark
Does this test replace colonoscopies and mammograms?
Mimi
Not yet, and maybe not ever for some cancers. The test is better at catching aggressive cancers that don't have existing screening. For cancers we already screen well—breast, colon—the existing tests are still the gold standard. This is about filling gaps, not replacing what works.
Il Polso
- Cancer's deadliest advantage has always been invisibility — this test threatens to take that advantage away by reading the genetic whispers tumors leave in the blood.
- With a 51.5% detection rate across all cancer stages and an even stronger 65.6% rate for cancers that currently have no screening options at all, the stakes for getting this right are enormous.
- The NHS is moving quickly, enrolling 140,000 people in a pilot programme beginning autumn 2021, with results expected by 2023 — a race against its own target of catching 75% of cancers at an early stage.
- The test is not a replacement for existing screenings but a powerful complement, best suited to catching the aggressive, fast-moving cancers that shed the most DNA and kill the fastest.
- If the pilot succeeds, Britain could shift from a fragmented system of cancer-specific tests to a single blood draw capable of surveying the body for dozens of diseases at once.
For generations, cancer has often announced itself too late — a diagnosis arriving only after the body has already begun to struggle. Now, a blood test developed by US company Grail offers a quieter form of vigilance, scanning the bloodstream for genetic fragments shed by tumors across more than fifty cancer types before a single symptom appears. Tested on thousands of patients and showing a false-positive rate of just 0.5 percent, the technology stands at the threshold of large-scale NHS trials, carrying with it the hope that early detection — long medicine's most elusive ambition — may at last become routine.
A blood test capable of detecting more than fifty types of cancer before any symptoms emerge has cleared a significant scientific milestone, with researchers saying it is accurate enough to sit alongside existing screening programmes — especially for people over fifty.
The test, developed by US company Grail, works by searching the bloodstream for cell-free DNA: fragments of genetic material that tumors shed as their cells break apart. By reading the chemical signatures of these fragments, the test can catch cancer's presence long before it makes itself known through pain or illness.
In a study of over 3,500 people, the test correctly identified cancer in 51.5% of cases across all disease stages, while raising false alarms in only 0.5% of cancer-free participants. For cancers with no existing screening tools — among them pancreatic, liver, and esophageal — the detection rate climbed to 65.6%. The test also correctly identified the tissue of origin in nearly nine out of ten positive cases.
Dr. Eric Klein of Cleveland Clinic, who led the research, noted that the cancers the test catches most readily tend to be the most aggressive — those that shed the most DNA and move the fastest. Quieter cancers, like prostate, still require their own dedicated tests, making this a complement to current screening rather than a wholesale replacement.
Published in the Annals of Oncology, the findings arrive as the NHS prepares a pilot programme enrolling 140,000 participants from autumn 2021, with results expected by 2023. The health service has set a target of diagnosing three-quarters of all cancers at an early stage — and a single blood test spanning dozens of cancer types could prove to be one of its most powerful tools for getting there.
A blood test that can spot more than fifty different cancers before a person feels sick or notices anything wrong has cleared a major hurdle toward becoming a standard screening tool. Scientists say the test is accurate enough to use alongside existing cancer checks, particularly for people over fifty and those at higher risk of the disease.
The test works by hunting for fragments of genetic material that tumors shed into the bloodstream. When cancer cells die or break apart, they release these fragments—known as cell-free DNA—into the blood in detectable amounts. The test, developed by a US company called Grail, looks for the chemical signatures of these fragments, essentially catching cancer's whisper before it becomes a shout.
Researchers tested the approach on 3,537 people: 2,823 who had cancer and 1,254 who did not. The results showed the test correctly identified cancer in just over half of all cases—51.5 percent—across every stage of disease. More importantly, it almost never raised a false alarm, wrongly flagging cancer in only 0.5 percent of people who did not have it. For cancers that currently have no screening options—pancreatic, liver, esophageal, and some blood cancers—the test performed even better, catching 65.6 percent of cases. The test also pinpointed which tissue in the body harbored the cancer in nearly nine out of ten cases.
Dr. Eric Klein, who led the research at Cleveland Clinic, explained that different cancers shed different amounts of genetic material into the blood. Tumors that leak more DNA tend to be the aggressive, harder-to-treat kinds—the very cancers that kill people fastest. The test catches these more readily. Other cancers, like prostate cancer, are quieter shedders and still require their own dedicated screening tests. This is why the blood test works best as a complement to existing checks, not a replacement.
The findings, published in the journal Annals of Oncology, arrive as the NHS prepares to test the approach on a much larger scale. Beginning in autumn 2021, the health service will enroll 140,000 people in a pilot program. Results are expected by 2023. The stakes are high: the NHS has set an ambitious goal of catching three-quarters of all cancers at an early stage, when treatment is most likely to succeed. A test that can detect dozens of cancer types from a single blood draw could help meet that target.
Klein noted that finding cancer early, when doctors have the most treatment options and the best chances of success, represents one of the most powerful tools medicine has to reduce cancer's burden. If this test proves itself in the NHS pilot, it could reshape how screening works in Britain—moving from a patchwork of cancer-specific tests to a single, comprehensive blood check that catches the disease before symptoms ever appear.
Citazioni salienti
Finding cancer early, when treatment is more likely to be successful, is one of the most significant opportunities we have to reduce the burden of cancer.— Dr. Eric Klein, Cleveland Clinic
This latest study provides further evidence that blood tests like this could help the NHS meet its ambitious target of finding three-quarters of cancers at an early stage, when they have the highest chance of cure.— Professor Peter Johnson, NHS national clinical director for Cancer
Vuoi la storia completa?
Leggi l'originale su Evening Standard ↗
Health & Medicine